4:55 PM
Nov 16, 2012
 |  BC Extra  |  Top Story

CHMP recommends Zaltrap

EMA's CHMP issued several positive opinions on Friday, including recommending approval of Zaltrap ziv-aflibercept from Sanofi (Euronext:SAN; NYSE:SNY) in combination with FOLFIRI chemotherapy to treat metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen. Sanofi is co-developing Zaltrap, which is approved in the U.S. for...

Read the full 244 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >